Kathryn Haviland
2020
Compensation breakdown
| Non-Equity Incentive Plan | $264,466 |
|---|---|
| Option Awards | $858,243 |
| Salary | $460,944 |
| Stock Awards | $771,353 |
| Other | $8,550 |
| Total | $2,363,556 |
Haviland received $858.2K in option awards, accounting for 36% of the total pay in 2020.
Haviland also received $264.5K in non-equity incentive plan, $460.9K in salary, $771.4K in stock awards and $8.6K in other compensation.
Rankings
In 2020, Kathryn Haviland's compensation ranked 4,799th out of 13,090 executives tracked by ExecPay. In other words, Haviland earned more than 63.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,799 out of 13,090 | 63rd |
Division Manufacturing | 1,953 out of 5,624 | 65th |
Major group Chemicals And Allied Products | 768 out of 2,257 | 66th |
Industry group Drugs | 661 out of 1,957 | 66th |
Industry Pharmaceutical Preparations | 500 out of 1,462 | 66th |
Pay ratio
| Kathryn Haviland's Pay | $2,363,556 |
|---|---|
| Median Employee's Pay | $332,124 |
| Pay Ratio | 7to 1 |
In 2020, the annual total compensation of Kathryn Haviland was $2,363,556.
The annual total compensation of the median employee at Blueprint Medicines was $332,124.
The ratio of Kathryn Haviland's pay to the pay of median employee was therefore 7 to one.
Haviland's colleagues
We found four more compensation records of executives who worked with Kathryn Haviland at Blueprint Medicines in 2020.